Company News

In 2025, Medgen Life Science achieved major breakthroughs in product innovation, international expansion, and industry standard-setting, delivering a year of high-quality growth.

Medgen's PoroGraft® oral bone filling material receives Class D medical device registration in Vietnam — the highest risk classification — becoming the company's third product approved in Vietnam and marking the systematic deployment of a multi-product portfolio in Southeast Asia.

Medgen Life Science has been named a "Quality, Safe, and Trusted Medical Aesthetics Service Provider" for the fourth consecutive year, delivering regenerative material solutions built to medical-grade standards.

Following its Vietnam Class C registration, Medgen's PRP preparation device secures Indonesia Class B medical device registration, adding another key market to the company's global expansion strategy.

Medgen's independently developed Platelet-Rich Plasma (PRP) preparation device receives Class C medical device registration in Vietnam, following its NMPA Class III approval in China, marking a key step in the company's Southeast Asian expansion.

Medgen Life Science has been officially designated as a Shenzhen "Specialized, Refined, Differentiated, and Novel" (SRDN) small and medium enterprise in recognition of its sustained technological innovation.

Medgen's independently developed bone graft material has been selected for the Shenzhen Key New Materials First-Batch Application Demonstration Directory, receiving official government recognition.

Medgen's independently developed BoneSwift™ pre-filled injectable bone filling material receives Class D medical device registration from Vietnam's Ministry of Health, the highest risk classification in Vietnam's regulatory system.

Medgen Life Science and Shanghai Sanyou Medical Devices (688085.SH) sign a national logistics service agreement for BoneSwift™ bone filling materials, launching a strategic orthopedic market partnership.

Hangzhou Qiantang Longyue Biotech and Medgen Life Science sign a strategic cooperation agreement, combining core strengths in precision medical devices and biomaterials to advance innovative product development and industrialization.

Medgen Life Science received the "Quality, Safe, and Trusted Medical Aesthetics Service Provider" award for the third consecutive year from the Shenzhen Plastic and Cosmetic Surgery Industry Association.

Medgen completes its Series A+ round exclusively invested by Yuansheng Venture Capital, bringing total funding across two rounds to nearly RMB 100 million within two months.

Exclusively invested by Huaxi Yuanyou Fund, Medgen Life Science completed its Series A financing to advance its multi-product regenerative repair material platform across orthopedics, aesthetics, and sports medicine.

Two group standards co-drafted by Medgen — covering injectable hydroxyapatite microsphere gel and degradation/collagen regeneration evaluation methods for facial soft tissue implants — have passed project approval review.

Medgen's major science and technology project on "Key Technologies for Composite Materials for Artificial Tendons" has received project funding from the Shenzhen Science and Technology Innovation Commission.

Medgen's independently developed BoneSwift™, China's first pre-filled injectable artificial bone, has completed all clinical trial subject follow-ups, with safety and efficacy fully validated.

Medgen Life Science was selected among the national top 100 at the "Innovation China" Innovation and Entrepreneurship Investment Conference, showcasing its resorbable artificial bone and regenerative repair materials.

Medgen Life Science won dual awards at the 6th China Medical Device Innovation and Entrepreneurship Competition with its "Inducible Bone Repair Material" and "Rotator Cuff Patch" projects.

Medgen Life Science has been officially certified as a National High-Tech Enterprise by China's Ministry of Science and Technology, recognizing the company's innovation capabilities, R&D strength, and technology commercialization.